Business Details
20 Years
experience
Innovative Botanical Medicines for a Healthier World
At Tasly Pharmaceuticals, we are dedicated to advancing healthcare through the integration of botanical science and modern pharmaceutical innovation. Founded in 2006 and headquartered in Rockville, Maryland, our mission is to develop safe, effective, and scientifically validated botanical medicines that offer natural, long-term alternatives while complementing conventional treatments. With over 500 worldwide regulatory approvals, our commitment to quality, safety, and compliance underscores our position as a leader in the pharmaceutical industry. Our flagship product, T89 (Dantonic), represents a groundbreaking achievement as the first herbal medicine-derived compound to complete an FDA Phase III global trial, demonstrating key clinical benefits such as enhancing blood circulation, boosting energy metabolism, and reducing blood viscosity.We prioritize patient-focused solutions and global health initiatives, actively seeking collaborations to expand our impact. Our expertise in U.S. regulatory submissions and deep understanding of the Chinese healthcare market enable us to bridge international partnerships, ensuring our innovations meet rigorous standards. Through decades of research and clinical validation, we strive to shape the future of botanical pharmaceuticals, delivering innovative treatments for cardiovascular health, oncology, liver disease, immunology, and stem cell research.
Services
Cardiovascular Botanical Drugs
Oncology Treatments
Liver Health Medicines
Stem Cell Research
Immunology Therapies
Clinical Trials
Regulatory Support
Drug Co-Development
Nutraceuticals
Global Health Solutions
Details
- Year established: 2006
Highlights and features
- We have 500+ worldwide regulatory approvals for our botanical medicines.
- Our T89 (Dantonic) is the first herbal-derived compound to complete an FDA Phase III global trial.
- Proven clinical efficacy in enhancing blood circulation and reducing blood viscosity.
- Dedicated to global health with a focus on patient-centered solutions.
- Expertise in integrating traditional botanical science with modern pharmaceutical research.
Services
Cardiovascular Botanical Drugs
Our cardiovascular botanical drugs, including T89 (Dantonic), are clinically proven to enhance blood circulation, reduce blood viscosity, and improve energy metabolism for chronic stable angina patients.
Oncology Treatments
We develop innovative oncology treatments targeting ovarian, prostate, breast, stomach, lung, and pancreatic cancers, with Phase II trials ongoing for TSL1502.
Liver Health Medicines
Our liver health programs focus on polypeptide-based treatments like HEPA44 for hepatitis B, with plans to seek U.S. clinical trial approval.
Stem Cell Research
Stem cell research initiatives, including UMSC01, aim to address acute myocardial infarction and ischemic stroke through Phase I clinical trials.
Immunology Therapies
Immunology therapies like TA06 utilize enzymatic digestion to enhance anti-PD-L1 antibody efficacy, improving clinical outcome predictions for immune-related diseases.
Questions
What does Tasly Pharmaceuticals specialize in?
We specialize in developing scientifically validated botanical medicines for cardiovascular health, oncology, liver disease, immunology, and stem cell research.
How does Tasly ensure product quality?
With 500+ worldwide regulatory approvals and rigorous clinical trials, we maintain strict quality, safety, and compliance standards for all our products.
What clinical trials are currently ongoing?
Ongoing trials include Phase III ORESA for T89 (cardiovascular), Phase II for TSL1502 (oncology), and plans for HEPA44 (liver health) in the U.S.
What is Tasly's approach to global health?
We prioritize patient-focused solutions and international collaborations to address unmet medical needs and improve healthcare access worldwide.
